PH12019502154A1 - 6-pyrimidin-isoindole derivative as erk1/2 inhibitor - Google Patents
6-pyrimidin-isoindole derivative as erk1/2 inhibitorInfo
- Publication number
- PH12019502154A1 PH12019502154A1 PH12019502154A PH12019502154A PH12019502154A1 PH 12019502154 A1 PH12019502154 A1 PH 12019502154A1 PH 12019502154 A PH12019502154 A PH 12019502154A PH 12019502154 A PH12019502154 A PH 12019502154A PH 12019502154 A1 PH12019502154 A1 PH 12019502154A1
- Authority
- PH
- Philippines
- Prior art keywords
- compound
- pyrimidin
- erk1
- inhibitor
- isoindole derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706327.2A GB201706327D0 (en) | 2017-04-20 | 2017-04-20 | A pharmaceutical compound |
| PCT/IB2018/052745 WO2018193410A1 (en) | 2017-04-20 | 2018-04-20 | 6-pyrimidin-isoindole derivative as erk1/2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12019502154A1 true PH12019502154A1 (en) | 2020-06-29 |
Family
ID=58795788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12019502154A PH12019502154A1 (en) | 2017-04-20 | 2019-09-20 | 6-pyrimidin-isoindole derivative as erk1/2 inhibitor |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11142518B2 (https=) |
| EP (1) | EP3612524B1 (https=) |
| JP (1) | JP7113846B2 (https=) |
| KR (1) | KR102652193B1 (https=) |
| CN (1) | CN110831939B (https=) |
| AU (1) | AU2018255935B2 (https=) |
| CA (1) | CA3059674A1 (https=) |
| DK (1) | DK3612524T3 (https=) |
| ES (1) | ES2994283T3 (https=) |
| FI (1) | FI3612524T3 (https=) |
| GB (1) | GB201706327D0 (https=) |
| IL (1) | IL269803B (https=) |
| MA (1) | MA52123A (https=) |
| MX (1) | MX2019012471A (https=) |
| MY (1) | MY203722A (https=) |
| PH (1) | PH12019502154A1 (https=) |
| SA (1) | SA519410253B1 (https=) |
| SG (1) | SG11201909189QA (https=) |
| TW (1) | TWI813566B (https=) |
| WO (1) | WO2018193410A1 (https=) |
| ZA (1) | ZA201907484B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068392T2 (hu) * | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| IL276232B2 (en) | 2018-03-02 | 2024-04-01 | Otsuka Pharma Co Ltd | Pyrazine derivatives, pharmaceutical compositions comprising them and their use for treating diseases |
| MX2021000795A (es) | 2018-07-24 | 2021-04-12 | Taiho Pharmaceutical Co Ltd | Compuestos heterociclicos para inhibir la actividad de shp2. |
| CN109608444B (zh) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | 含异吲哚啉酮的erk抑制剂及其制备方法与用途 |
| GB201911928D0 (en) | 2019-08-20 | 2019-10-02 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| TW202140024A (zh) * | 2020-01-24 | 2021-11-01 | 日商大鵬藥品工業股份有限公司 | Shp2抑制劑嘧啶酮與新穎癌症醫藥併用於癌症之抗腫瘤活性之增強 |
| CN115443274B (zh) * | 2020-04-30 | 2025-04-25 | 勤浩医药（苏州）有限公司 | 含苯基并内磺酰胺的化合物 |
| CN113967198A (zh) * | 2020-07-24 | 2022-01-25 | 鲁南制药集团股份有限公司 | 一种甾体cyp17抑制剂胶囊及其制备方法 |
| US20230312564A1 (en) * | 2020-08-21 | 2023-10-05 | Shanghai Ringene Biopharma Co., Ltd. | Aromatic ring-lactam compound, preparation method therefor and use thereof |
| KR20240021198A (ko) * | 2021-06-11 | 2024-02-16 | 오츠카 세이야쿠 가부시키가이샤 | Erk 억제제의 제조 방법 |
| US11931370B2 (en) * | 2021-10-08 | 2024-03-19 | Slayback Pharma Llc | Stable pharmaceutical compositions of cyclophosphamide |
| US20240415835A1 (en) * | 2021-10-26 | 2024-12-19 | Otsuka Pharmaceutical Co., Ltd. | Compositions comprising an erk inhibitor |
| CN114085213B (zh) * | 2022-01-20 | 2022-03-25 | 苏州国匡医药科技有限公司 | 一种arv-471的制备方法 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5958934A (en) | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
| JP2003504301A (ja) | 1998-04-01 | 2003-02-04 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | インテグリンアンタゴニスト |
| CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| MXPA05011523A (es) | 2003-04-30 | 2006-01-23 | Inst For Pharm Discovery Inc | Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas. |
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| EP1663204B1 (en) | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| UA84930C2 (ru) | 2004-05-14 | 2008-12-10 | Вертекс Фармасьютикалс Инкорпорейтед | Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения |
| WO2006113769A1 (en) | 2005-04-15 | 2006-10-26 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| KR101417136B1 (ko) | 2005-12-13 | 2014-08-07 | 머크 샤프 앤드 돔 코포레이션 | Ｅｒｋ 억제제인 폴리사이클릭 인다졸 유도체 및 이를 포함하는 약제학적 조성물 |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| CA2654670A1 (en) | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | New compounds |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| WO2009039635A1 (en) | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| EP2215074B1 (en) | 2007-09-27 | 2014-02-19 | The United States of America, as Represented by the Secretary, Department of Health and Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| WO2009092432A1 (en) | 2008-01-24 | 2009-07-30 | Merck Patent Gmbh | Beta-amino acid derivatives for treatment of diabetes |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| US8084620B2 (en) | 2008-12-19 | 2011-12-27 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| EP2429987A4 (en) | 2009-05-15 | 2012-10-03 | Korea Res Inst Chem Tech | AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| WO2010151747A1 (en) | 2009-06-26 | 2010-12-29 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimine compounds and methods of making and using same |
| WO2011008931A2 (en) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| KR101758046B1 (ko) | 2009-12-22 | 2017-07-14 | 버텍스 파마슈티칼스 인코포레이티드 | 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제 |
| AU2010336027A1 (en) | 2009-12-23 | 2012-07-19 | Auckland Uniservices Limited | Compounds, preparations and uses thereof |
| NZ601526A (en) | 2009-12-31 | 2014-07-25 | Piramal Entpr Ltd | Inhibitors of diacylglycerol acyl transferase |
| WO2012002527A1 (ja) | 2010-07-02 | 2012-01-05 | あすか製薬株式会社 | 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤 |
| PE20130774A1 (es) | 2010-07-29 | 2013-06-26 | Rigel Pharmaceuticals Inc | Compuestos heterociclicos activadores de ampk y metodos para emplearlos |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| DK2820009T3 (en) | 2012-03-01 | 2018-04-16 | Array Biopharma Inc | Serine / threonine kinase inhibitors |
| CN104583195B (zh) | 2012-09-12 | 2018-08-17 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物 |
| US20150272939A1 (en) | 2012-10-02 | 2015-10-01 | Yale University | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase |
| AU2013337717B2 (en) | 2012-11-01 | 2018-10-25 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| MX2015009952A (es) | 2013-02-08 | 2015-10-05 | Celgene Avilomics Res Inc | Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos. |
| US20140357636A1 (en) | 2013-02-21 | 2014-12-04 | Wayne Rothbaum | Treatment of Skeletal-Related Disorders |
| EA034866B1 (ru) | 2013-08-30 | 2020-03-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Замещенные пиримидиновые ингибиторы bmi-1 |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| WO2015108861A1 (en) * | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CN110229142A (zh) | 2014-04-04 | 2019-09-13 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| WO2015157556A1 (en) | 2014-04-09 | 2015-10-15 | Kadmon Corporation, Llc | Treatment of gvhd |
| WO2016025649A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a dot1l inhibitor and related methods |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| WO2016162325A1 (en) | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
| BR112017026159A2 (pt) | 2015-06-15 | 2018-08-14 | Asana Biosciences, Llc | inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer |
| HUE068392T2 (hu) | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| LT3374359T (lt) | 2015-11-09 | 2020-03-25 | Astrazeneca Ab | Dihidroimidazopirazinono deriniai, tinkami panaudoti vėžio gydymui |
| EP3492462B1 (en) | 2016-07-26 | 2023-08-30 | Shenzhen TargetRx, Inc. | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
-
2017
- 2017-04-20 GB GBGB1706327.2A patent/GB201706327D0/en not_active Ceased
-
2018
- 2018-04-20 CA CA3059674A patent/CA3059674A1/en active Pending
- 2018-04-20 AU AU2018255935A patent/AU2018255935B2/en active Active
- 2018-04-20 ES ES18722731T patent/ES2994283T3/es active Active
- 2018-04-20 IL IL269803A patent/IL269803B/en unknown
- 2018-04-20 WO PCT/IB2018/052745 patent/WO2018193410A1/en not_active Ceased
- 2018-04-20 SG SG11201909189Q patent/SG11201909189QA/en unknown
- 2018-04-20 DK DK18722731.9T patent/DK3612524T3/da active
- 2018-04-20 KR KR1020197033128A patent/KR102652193B1/ko active Active
- 2018-04-20 CN CN201880024602.7A patent/CN110831939B/zh active Active
- 2018-04-20 MX MX2019012471A patent/MX2019012471A/es unknown
- 2018-04-20 MA MA052123A patent/MA52123A/fr unknown
- 2018-04-20 US US16/604,002 patent/US11142518B2/en active Active
- 2018-04-20 MY MYPI2019005656A patent/MY203722A/en unknown
- 2018-04-20 TW TW107113537A patent/TWI813566B/zh active
- 2018-04-20 JP JP2019555918A patent/JP7113846B2/ja active Active
- 2018-04-20 FI FIEP18722731.9T patent/FI3612524T3/fi active
- 2018-04-20 EP EP18722731.9A patent/EP3612524B1/en active Active
-
2019
- 2019-09-20 PH PH12019502154A patent/PH12019502154A1/en unknown
- 2019-10-03 SA SA519410253A patent/SA519410253B1/ar unknown
- 2019-11-12 ZA ZA2019/07484A patent/ZA201907484B/en unknown
-
2021
- 2021-09-01 US US17/464,166 patent/US12030873B2/en active Active
-
2024
- 2024-05-31 US US18/679,934 patent/US20250002481A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201907484B (en) | 6-pyrimidin-isoindole derivative as erk1/2 inhibitor | |
| PH12022551379A1 (en) | Substituted tetrahydrofurans as modulators of sodium channels | |
| PH12015501661B1 (en) | Pyridone amides as modulators of sodium channels | |
| MX340064B (es) | Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos. | |
| YU66101A (sh) | Nova jedinjenja i kompozicije kao inhibitori proteaze | |
| MX2019009564A (es) | Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino ) pirimidin-4-il) benzamida. | |
| MX2019000536A (es) | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. | |
| PH12017502067A1 (en) | Insecticidal arylpyrrolidines, method for synthesizing same, and use thereof as agents for controlling animal pests | |
| PE20170148A1 (es) | Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer | |
| NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
| PH12019500569A1 (en) | Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors | |
| MX2021006682A (es) | Inhibidores de descarboxilasa para el tratamiento de la enfermedad de parkinson. | |
| MY198008A (en) | Crystal of benzofuran derivative free base and preparation method | |
| PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| JOP20200133A1 (ar) | طريقة لتحضير حمض (3s)-3-(4-كلورو-3-{[(2s،3r) -2-(4-كلورو فنيل) -4، 4، 4-ثلاثي فلورو-3-مثيل بيوتانويل] أمينو} فنيل) -3- بروبيل حلقي بروبانويك والشكل البلوري منه لاستخدامه كمركب فعال صيدلانياً | |
| PH12019501785A1 (en) | Intranasal composition comprising betahistine | |
| PH12020551736A1 (en) | The crystalline forms of a compound | |
| PH12019502852A1 (en) | Novel compounds activating the nrf2 pathway | |
| MX2019004345A (es) | Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida. | |
| MX2019009059A (es) | Procesos enzimaticos para la preparacion de acido (±)-2-(difluorometil)-1-(alcoxicarbonil)-ciclopropancarboxilico y +acido (±)-2-(vinil)-1-(alcoxicarbonil)-ciclopropancarboxilico. | |
| CY1125023T1 (el) | Διεργασια για την παρασκευη toy (n-((1r,2s,5r)-5-(τριτοταγους-βουτυλαμινο)-2-((s)-3-(7-τριτοταγους-βουτυλπυραζολο[1,5-α][1,3,5]τριαζιν-4-υλαμινο)-2-οξοπυρρολιδιν-1-υλ)κυκλοεξυλ) ακεταμιδιου | |
| MX2020008082A (es) | Compuestos y composiciones para el tratamiento del dolor. | |
| NZ727251A (en) | Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s | |
| JOP20180070B1 (ar) | مثبطات إنزيم كيناز بروتين يتفاعل مع مستقبل 1 |